ACTG Network

Meet ACTG Past Chair, Judith Currier, MD, MSc! Her thirty year career in infectious disease spans HIV therapeutics, HIV related complications including cardiovascular disease, women's health, and antiretroviral therapy.

#ACTGNetwork

Since 1987, ACTG has brought together a global network of dedicated investigators, staff, and community members with the common purpose of finding new treatments and cures for infectious diseases. In 2025, ACTG defined the pillars for success in four key areas.

"Almost half of HIV+ participants had neurocognitive impairment at baseline before ART, based on local norms. With ART initiation, there were significant overall reductions in neurocognitive impairment over time..."

pubmed.ncbi.nlm.nih.gov/30219843/

Photo of Dr. Joe Eron.

As ACTG Chair, Joe Eron, MD. says, "Our success depends on the strength of our leadership, investigators, sites, participants and communities with whom we collaborate. I want to emphasize the vital role each of you plays in our mission."

us13.campaign-archive.com?e=__test_ema...

#ACTGNetwork

Clinical trials are a vital step in testing the safety and efficacy of a drug for the intended population. New drug treatments can take 10 - 15 years of research and trials before going to market. Click on the link to learn more about the clinical trials process.

actgnetwork.org/homepage/abo...

Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314 - PubMed NCT01949116.

This phase 2, randomized, double blind, multi-center trial looked at how low dose methotrexate performed in chronic inflammation in treated HIV infection.

pubmed.ncbi.nlm.nih.gov/30219823/

Meet Yijia Li, MD. Dr. Li is an assistant clinical professor of medicine and a HIV researcher. When it comes to advice for young investigators, Dr. Li says, “It is definitely not an easy path, but if this is your passion, go for it!”.

us13.campaign-archive.com?e=__test_ema...

Graphic with celebrating research findings.

ACTG researched the efficacy of a three month clofazimine and high dose rifapentine containing treatment of tuberculosis versus a six month treatment in the CLO-FAST trial. Interim findings published in 2023, found the three month treatment to be ineffective.

clinicaltrials.gov/study/NCT043...

Celebrating Research!
In 2021, this study found that a four month treatment to be non-inferior to a six month treatment of tuberculosis, when comparing the efficacy of a rifapentine-moxifloxacin based treatment to the control group.

Like and follow for more. 🙌

pmc.ncbi.nlm.nih.gov/articles/PMC...

“People can disengage when processes become overly administrative. We need to make space for joy in science, which sustains us through the challenging times. Effective processes and administration are foundational for a clinical trials network, but nurturing joy is equally crucial.” - Dr. Hunt 👏

Have you tested for HIV recently? In 2019, 165,000 people in the United States were living with HIV unknowingly. Globally, 5.4 million people did not know that they were HIV positive in 2023. Test frequently.

#ACTGNetwork

www.reprievetrial.org/factors-affe...

Meet, Fredrick Sawe, MBCHB, MMED. Dr. Sawe is a 2023 award recipient of the ACTG James Hakim International Investigators Mentorship Award, recognizing his work in advancing the care of people living with HIV/AIDS and his service to the ACTG network.

actgnetwork.org/newsletter/

Informed consent is an important step in the clinical trial process that ensures that the patient, or participant has and understands all of the information to make an informed decision about whether or not to receive treatment.

Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort Time-updated analyses of the REPRIEVE cohort suggest that antiretroviral therapies featuring abacavir backbones increase hazard of major adverse cardiovasc

"Antiretroviral therapies with ABC backbones are associated with an increase in MACE compared to TFV backbones among people living with HIV at low-to-moderate cardiovascular risk."

#ACTGNetwork

academic.oup.com/ofid/article...

As a member of ACTG, Dr. Manne-Goehler has enjoyed being a part of a community of researches dedicated to HIV research. When asked what her advice is for young investigators, she encouraged persistence against challenges.

Visit the website to learn more!
actgnetwork.org/newsletter/

#ACTGNetwork

We have come a long way in the field of HIV/AIDS treatment thanks to the dedication and hard work of researchers and staff. Gratitude to everyone who has been on the journey to create a world free of HIV/AIDS. 🙌

#ACTGNetwork

Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function - PubMed We observed minimal declines in physical function over 5 years of follow-up among middle-aged PWH, with no differences among PWH randomized to pitavastatin compared to placebo. This finding, combined ...

"We observed minimal declines in physical function over 5 years of follow-up among middle-aged PWH, with no differences among PWH randomized to pitavastatin compared to placebo."

pubmed.ncbi.nlm.nih.gov/39159048/

#HIV #actgnetwork #statin

“Our team at UNC has followed many dedicated participants on this protocol, and we are so grateful to these participants for their willingness to contribute to help others.” - Joe Eron, MD

globalhealth.unc.edu/2025/04/clin...

Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers - PubMed ART in HIV controllers reduces T-cell activation and improves markers of immune exhaustion. These results support the possible clinical benefits of ART in this population.

Celebrating Research - High five for five years since this research was published 🙌

"Antiretroviral Therapy Reduces T-Cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers"

pubmed.ncbi.nlm.nih.gov/31131858/

ACTG April Young Investigator Spotlight, Dr. Akarin Hiransuthikul MD, MSc

"Starting as an investigator in the ACTG's projects early in my career gave me firsthand experience in the environment of a world class research team. It influenced how I design and conduct my own studies, as well as how I mentor the next generation of researchers."

actgnetwork.org/newsletter/

Today is National Youth HIV/AIDS Awareness Day in the United States.

In recent years, the number of new HIV/AIDS diagnoses has decreased among people aged 13 - 24. In 2022, there were 6,400 new HIV/AIDS diagnoses , a 30 percent decrease from 2018.

#NYHAAD #HIVprevention #AIDSAwareness

ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen ...

New research finds that it is estimated that participants who switched to an integrase inhibitor based regimen had an increased risk of developing obesity, diabetes, hypertension, and metabolic syndrome.

Read further research findings in the press release,

www.globenewswire.com/news-release...

Sign up for the ACTG newsletter to learn more about members (link below).

Meet Dr. Shibani Mukerji! 🧠 🩺
As a trained neuroscientist and neurologist, her work meets at the intersection of infectious disease and neurology.

sighttps://actgnetwork.org/newsletter/

#ACTGNetwork #HIVresearch